New Delhi, November 28, 2023 — Concerns about the integrity of India’s rabies vaccine supply are swirling after Australian health authorities flagged counterfeit doses of the Abhayrab vaccine circulating since November 2023. But is the situation as widespread as initially suggested?
Vaccine Maker Disputes Australian Alert on Counterfeit Rabies Doses
Indian Immunologicals Limited (IIL) is pushing back against claims of widespread fake rabies vaccine doses.
- Indian Immunologicals Limited (IIL) has refuted claims made by Australian health authorities regarding counterfeit batches of its Abhayrab vaccine.
- The alert from the Australian Technical Advisory Group cited circulation of fake doses beginning in November 2023.
- IIL asserts that every vaccine batch undergoes rigorous testing and is approved by the Central Drugs Laboratory before distribution.
What does this mean for rabies prevention? Rabies is a deadly, but preventable, viral disease. Ensuring the authenticity and quality of vaccines is paramount to protecting public health, and IIL is assuring the public of its commitment to safety.
In a statement released today, IIL clarified its position regarding the alert issued by the Australian Technical Advisory Group on the circulation of counterfeit batches of the Abhayrab vaccine. The company maintains that the alert does not accurately reflect the current situation.
IIL emphasized its stringent quality control measures, stating that every batch of vaccine manufactured in India is thoroughly tested and released by the Central Drugs Laboratory before being made available for sale or administration. This multi-layered process is designed to guarantee the safety and efficacy of the vaccine.
The company’s response aims to reassure healthcare professionals and the public about the reliability of the Abhayrab vaccine, a crucial tool in preventing rabies transmission. The incident underscores the ongoing challenges in combating counterfeit pharmaceuticals globally.